Invitae
Invitae Bets on Oncology Portfolio to Drive Growth as it Streamlines, Integrates Test Services
Premium
In the wake of last year's massive restructuring, Invitae is focused on developing its Personalized Cancer Monitoring product while integrating other oncology offerings.
JP Morgan Healthcare Conference, Day 3: Invitae, NanoString, Bio-Rad, Olink, More
Highlights from the third day included Invitae's plans for its testing business and updates on instrument placements by NanoString Technologies and Olink.
Invitae Preliminary Q4 Revenues in Line With Wall Street Estimate
Exited businesses and geographies led a year-over-year Q4 revenue decline, while annual revenues are expected to grow relative to 2021.
Losses Deep and Widespread as GenomeWeb Top 40 Drops 34 Percent in 2022
All but two Top 40 companies declined, with over half losing more than 50 percent of their value and 13 companies losing three-quarters of their value or more.
GenomeWeb Top 40 Down 3 Percent in December, Though More Resilient Than Broader Market
The Dow Jones Industrial Average was down 4 percent, while the Nasdaq fell 9 percent, and the Nasdaq Biotech Index was down 3 percent.